XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities    
Net loss before redeemable noncontrolling interest $ (38,778) $ (52,090)
Adjustments to reconcile net loss before redeemable noncontrolling interest to net cash used in operating activities:    
Research and development acquired license   27,381
Anti-dilution share issuance compensation   2,186
Share-based compensation expense 13,981 5,075
Change in fair value of note payable   2,244
Change in fair value of research and development license consideration liability   1,854
Change in fair value of private placement warrants 5,240 236
Depreciation and amortization 4  
Foreign exchange transaction (gain)/loss (31) 6
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 283 (524)
Accounts payable and accrued expenses 2,049 2,631
Net cash used in operating activities (17,252) (11,001)
Cash flows from investing activities    
Purchase of fixed assets (30)  
Purchase of research and development license (5,000) (8,000)
Net cash used in investing activities (5,030) (8,000)
Cash flows from financing activities    
Proceeds from issuance of Class A Ordinary Shares upon Closing of Business Combination   56,683
ATM transaction costs (38)  
Settlement of note payable   (10,000)
Payment of deferred transaction costs (52) (1,184)
Net cash provided by financing activities 110,697 121,293
Net increase in cash and cash equivalents 88,415 102,292
Cash and cash equivalents, beginning of period 99,806 1,567
Cash and cash equivalents, ending of period 188,221 103,859
Supplemental Disclosure of Non-Cash Investing and Financing Activities    
Issuance of Class A Ordinary Shares in exchange for private placement warrants 6,230  
Adjustments to redeemable noncontrolling interest from redemption value to carrying value 7,017  
Accretion of redeemable noncontrolling interest to redemption value 4,577  
Unpaid ATM transaction costs included in accounts payable and accrued expenses 588  
Restricted share units withheld to pay employee withholding taxes that are included in accounts payable and accrued expenses 318  
Purchase of property and equipment included in accounts payable and accrued expenses 18  
Accrued 2023 Lilly License consideration   10,000
Deemed dividend to redeemable noncontrolling interest   10,875
Issuance of Class A Ordinary shares for 2023 Lilly License   7,840
Conversion of Series A-1 convertible preferred shares for Class A Ordinary Shares   14,686
Share-based equity issuance costs   5,590
Settlement of research and development license consideration liability   4,488
Assumption of public and private placement warrants in connection with Business Combination   3,715
Reclassification of deferred offering costs to additional paid-in capital   4,015
Reclassification of public warrant liability to equity   2,001
Issuance of Call Right to noncontrolling interest   1,541
Private Placement April 2024    
Cash flows from financing activities    
Proceeds from issuance of Class A Ordinary Shares in connection with April 2024 Private Placement, net of $7.2 million of transaction costs 55,223  
Proceeds from issuance of Pre-Funded Warrants in connection 50,030  
At The Market Offering    
Cash flows from financing activities    
Proceeds from issuance of Class A Ordinary Shares upon Closing of Business Combination $ 5,534  
Private Placement April 2023    
Cash flows from financing activities    
Proceeds from issuance of Class A Ordinary Shares upon Closing of Business Combination   59,724
Proceeds from issuance of Pre-Funded Warrants in connection   $ 16,070